PTX3-targeted prophylaxis
PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia
- Principal investigator: Prof. Dr. Johan Maertens
- More information: NCT03828773
- Internal reference number: S62099
FMGX-CS-302
An interventional Phase 3, open-label, two-cohort study to investigate the efficacy and safety of fosmanogepix in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds
- Principal investigator: Prof. Dr. Johan Maertens
- More information: NCT06925321
- Internal reference number: S70029
EL219.IV.2.04
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 versus Standard of Care (Liposomal Amphotericin B followed by Voriconazole) for Early Antifungal Therapy of Suspected Invasive Mould Infections
- Principal investigator: Prof. Dr. Johan Maertens
- More information: NCT07215273
- Internal reference number: S71276
Vragen en contact
-
Via deze weg kunt u geen afspraak maken.